April 10, 2020

Spring has sprung! The Bio X Cell team is enjoying the longer days, the warmer weather, and the birds singing. We all sincerely hope you are doing well and enjoying nature\'s beauty as spring unfolds.

COVID-19 Update

Many states have issued \"shelter in place” orders causing universities as well as other research organizations to temporarily close their doors to non-essential staff. We recognize that there are thousands of ongoing, long-term experiments being conducted in animal models that must continue.

Given the critical role we are playing in providing reagents needed for this life-saving research, Bio X Cell is exempt from restrictions in our home state of New Hampshire and our neighboring state of Vermont. As such, we have made necessary modifications to our workflow in order to serve you to the best of our ability while taking the utmost precautions to protect our employees and customers. We will strive to fill orders in a timely manner and will also be double-checking that you will have someone available on site to receive them and store them properly.

Employee Spotlight

Bill Wood started with Bio X Cell in February 2000. He is now the manager of the Fermentation Department. He oversees the culturing and growing of catalogs cell lines, develops subclones, maintains our frozen cell banks, and oversees OSHA compliance. Bill has a BS in Cell Biology and Biochemistry from the University of California San Diego. Past job experience includes working in the Infections Disease Lab at read more...

Introducing...

InVivoMAb anti-mouse FGL-1

FGL-1 was identified as the major inhibitory ligand for the immune checkpoint receptor LAG-3.

This Antibody Is Useful For:

• in vivo FGL-1 blockade
• in vitro FGL-1 blockade
• Flow cytometry
• Immunohistochemistry (paraffin)

Recent Research Featuring FGL-1

FGL-1 is a major inhibitory receptor of LAG-3 and its blockade can potentiate anti-tumor T cell responses

Lymphocyte-activation gene 3 (LAG-3) is a receptor that negatively regulates the proliferation, activation, and effector function of T cells. Currently, monoclonal antibodies that block the interaction of LAG-3 with its canonical ligand, MHC-II, are being evaluated for their antitumor activity read more...